THE ROLE OF A NEW BIOMARKER GROWTH DIFFERENTIATION FACTOR 15 IN PROGNOSIS OF PATIENTS WITH ACUTE CORONARY SYNDROME AND TYPE 2 DIABETES MELLITUS

  • M. P. Kopytsya GI «L. T. Malaya Therapy National Institute of the National Academy of medical science of Ukraine», Kharkov, Ukraine
  • O. V. Petyunina Government institution «L. T. Malaya Therapy National Institute of the National Academy of medical science of Ukraine»
  • I. R. Vyshnevska Government institution «L. T. Malaya Therapy National Institute of the National Academy of medical science of Ukraine»
  • N. V. Tytarenko Government institution «L. T. Malaya Therapy National Institute of the National Academy of medical science of Ukraine»
  • Y. V. Hilova Government institution «L. T. Malaya Therapy National Institute of the National Academy of medical science of Ukraine»
Keywords: biomarkers, GDF 15, diabetes mellitus, acute coronary syndrome, prognosis

Abstract

Numerous studies confirm worse results in diabetic patients with acute coronary syndrome (ACS) compared with non-diabetic patients. Different mechanisms underlie the adverse outcomes of ACS and diabetes mellitus. In this connection, a special place is occupied by the study of new biomarkers that reflect the complex pathogenic processes in these patients. Purpose: to investigate the role of the biomarker GDF 15 in prognosis of adverse outcomes in type 2 diabetes mellitus (DM2T) patients with ACS. Materials and methods: 73 patients with different forms of ACS were screened. Levels of biomarkers: GDF 15, N-terminal pro brain natriuretic peptide (NT-pro BNP) and C-reactive protein (C-RP) were determined. The follow up period was 1 year. Endpoint was defined as lethal outcome. Results: significant differences in GDF 15 level has been found, prognostic value of GDF 15 was estimated in patients with DM2T, using a ROC-analysis. Threshold level of GDF 15 has been determined as 3894 pg/ml, with sensitivity of 64 % and specificity of 75 %. Conclusion: Patients with ACS and DM2T more often had a history of different cardiovascular diseases and risk factors compared to patients without diabetes. GDF 15 level was significantly higher in patients with ACS who had history of DM2T.

Downloads

Download data is not yet available.

Author Biographies

M. P. Kopytsya, GI «L. T. Malaya Therapy National Institute of the National Academy of medical science of Ukraine», Kharkov, Ukraine

Prospect Lyubov Malyoy, 2A, Kharkiv, Kharkiv region, 61000

O. V. Petyunina, Government institution «L. T. Malaya Therapy National Institute of the National Academy of medical science of Ukraine»

Prospect Lyubov Malyoy, 2A, Kharkiv, Kharkiv region, 61000

I. R. Vyshnevska, Government institution «L. T. Malaya Therapy National Institute of the National Academy of medical science of Ukraine»

Prospect Lyubov Malyoy, 2A, Kharkiv, Kharkiv region, 61000

N. V. Tytarenko, Government institution «L. T. Malaya Therapy National Institute of the National Academy of medical science of Ukraine»

Prospect Lyubov Malyoy, 2A, Kharkiv, Kharkiv region, 61000

Y. V. Hilova, Government institution «L. T. Malaya Therapy National Institute of the National Academy of medical science of Ukraine»

Prospect Lyubov Malyoy, 2A, Kharkiv, Kharkiv region, 61000

References

Keller PF, Carballo D, Roffi M. Diabetes in acute coronary syndromes // Minerva Med. – 2010. – № 101(2). – P. 81–104.

Erlih A.D., Gratsianskiy N.A. Ostriy koronarniy sindrom u bolnich sakharnim diabetom: realnaya praktika rossiyskih statsionarov (po resultatm registra RECORD) // Kardiologia/Saharniy diabet. – 2012. – № (2). – P.27–31.

Adela R, Banerjee SK. GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective // J Diabetes Research. – 2015. – № ID 490842.

Q. Ding, T. Mracek, P. Gonzalez-Muniesa et al. Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes // Endocrinology. – 2009. - vol. 150, №. 4. – PP. 1688–1696.

M. Carstensen, C. Herder, E. J. Brunner et al. Macrophage inhibitory cytokine-1 is increased in individuals before type 2 diabetes diagnosis but is not an independent predictor of type 2 diabetes: the Whitehall II study // European Journal of Endocrinology. – 2010. – vol. 162, №. 5. – PP. 913–917.

T. Kempf, M. Eden, J. Strelau et al. The transforming growth factor-β superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury // Circulation Research. – 2006. – vol. 98, №. 3. – PP. 351–360

T. Kempf, A. Guba-Quint, J. Torgerson et al. Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial // European Journal of Endocrinology. – 2012. – vol. 167, №. 5. – PP. 671–678

G. Vila, M. Riedl, C. Anderwald et al. The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients // Clinical Chemistry. – 2011. – vol. 57, №. 2, PP. 309–316.

A. Dominguez-Rodriguez, P. Abreu-Gonzalez, and P. Avanzas. Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus // The American Journal of Cardiology. – 2014. – vol. 114, №. 6. – PP. 890–894.

How to Cite
Kopytsya, M. P., Petyunina, O. V., Vyshnevska, I. R., Tytarenko, N. V., & Hilova, Y. V. (1). THE ROLE OF A NEW BIOMARKER GROWTH DIFFERENTIATION FACTOR 15 IN PROGNOSIS OF PATIENTS WITH ACUTE CORONARY SYNDROME AND TYPE 2 DIABETES MELLITUS. The Journal of V. N. Karazin Kharkiv National University, Series "Medicine", (32), 12-18. Retrieved from https://periodicals.karazin.ua/medicine/article/view/7821
Section
Clinical research